These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25013066)

  • 21. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL; Williamson C; Morris L
    Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Kelsoe G; Moody MA; Haynes BF
    Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
    Montefiori DC; Mascola JR
    Curr Opin HIV AIDS; 2009 Sep; 4(5):347-51. PubMed ID: 20048696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
    Walker LM; Burton DR
    Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological mechanisms of inducing HIV immunity in infants.
    Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
    Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV Vaccination: A Roadmap among Advancements and Concerns.
    Trovato M; D'Apice L; Prisco A; De Berardinis P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.
    Mu Z; Haynes BF; Cain DW
    Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 neutralizing antibodies: understanding nature's pathways.
    Mascola JR; Haynes BF
    Immunol Rev; 2013 Jul; 254(1):225-44. PubMed ID: 23772623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.